Impact of pregnancy on papillary thyroid carcinoma prognosis

Driouich, Yasmine; Haraj, Nassim Essabah; Aziz, S. El; Chadli, Asma

doi:10.11604/pamj.2021.38.261.22762

Cited by 10 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our study agree with the few available in the literature, all coming from non-European Centers [ 7 , 8 , 9 , 10 , 11 ], and here reviewed, confirming that the vast majority of patients with known biochemical or structural persistence of disease at the time of conception remain stable or slowly progresses during pregnancy.…”

Section: Discussionsupporting

confidence: 91%

“…The complete TNM assessment was performed in three out of five post-surgery studies [ 8 , 11 ], and only three out of five studies assessed ATA risk for patients [ 9 , 10 ], including the present one. The DRS, which evaluates the response to therapy after initial treatments, was evaluated only in the large American series [ 9 ] and in the present study.…”

Section: Resultsmentioning

confidence: 99%

“…Among the available studies, biochemical or structural progression after pregnancy ranged from 0 to 15% and from 8 to 31%, respectively. The mean follow-up was not reported in 2 studies [ 8 , 9 ] and was of few months in 2 additional studies [ 7 , 10 ], while long follow-ups are available only for the Yamazaki’s series (131 months) [ 11 ] and for the present study (97 ± 79.4).…”

Section: Resultsmentioning

confidence: 99%

“…By contrast, for women with biochemical or structural persistence, the available studies are more limited, and the data are controversial. To date, only five studies have been reported on this topic, and the results indicate that pregnancy can occasionally be associated with a slight increase in already existing metastatic lesions, though without a significant impact on progression and mortality risk [ 7 , 8 , 9 , 10 , 11 ]. The study, including the largest series of persistent patients, showed that none of the patients with an excellent, indeterminate, or biochemical incomplete response to therapy prior to pregnancy developed structural persistence during pregnancy or postpartum, while women with structural disease persistence before pregnancy were more likely to have structural disease progression (16%), 8% of them requiring additional therapy [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Persistent Thyroid Carcinoma and Pregnancy: Outcomes in an Italian Series and Review of the Literature

Colombo

Leo

Giancola

et al. 2022

Cancers

View full text Add to dashboard Cite

Scanty data are available on the progression risk in patients with persistent thyroid cancer (TC) before pregnancy. We aimed to evaluate this topic in our series and to review available literature data. This was a retrospective study performed in a tertiary care Italian TC center. We included 8 patients with persistent papillary TC who became pregnant after initial treatments (mean time interval of 62 months). Seven patients had the structural disease (lung and/or neck node metastases), while one patient had biochemical persistence. During a mean follow-up of 97 months, none of the patients showed disease progression either during pregnancy or during a follow-up of at least 12 months after delivery, and no additional treatments were needed. A sequential biochemical evaluation showed that thyroglobulin levels can significantly increase during pregnancy, returning to preconception levels after delivery. In conclusion, our data confirm that pregnancy is not associated with disease progression in patients with stable local and/or distant persistence before conception. Thus, pregnancy should not be contraindicated in metastatic women, although a precise clinical characterization, including the disease stage at diagnosis, the ATA risk class, and the dynamic risk stratification, should be conducted before conception.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Persistent Thyroid Carcinoma and Pregnancy: Outcomes in an Italian Series and Review of the Literature

Colombo

Leo

Giancola

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Papillary thyroid carcinoma (PTC), which is the most common kind of differentiated thyroid malignancy and accounts for 80% of all cases, is regarded as the least invasive type of thyroid cancer [ 31 , 32 ]. Its 10-year recurrence-free survival rate is about 95.5% [ 33 ].…”

Section: The Role Of Eva1a In Papillary Thyroid Cancermentioning

confidence: 99%

The Emerging Role of EVA1A in Different Types of Cancers

Zhao

Liu

Yang

et al. 2022

IJMS

View full text Add to dashboard Cite

Eva-1 homolog A (EVA1A), also known as transmembrane protein 166 (TMEM166) and regulator of programmed cell death, is an endoplasmic reticulum associated protein, which can play an important role in many diseases, including a variety of cancers, by regulating autophagy/apoptosis. However, the related mechanism, especially the role of EVA1A in cancers, has not been fully understood. In this review, we summarize the recent studies on the role of EVA1A in different types of cancers, including breast cancer, papillary thyroid cancer, non-small cell lung cancer, hepatocellular carcinoma, glioblastoma and pancreatic cancer, and analyze the relevant mechanisms to provide a theoretical basis for future related research.

show abstract